Immuno-Oncology Services | NMI TT Pharmaservices

home contact company.overview news sitemap print privacy

Immuno-Oncology Services


NMI-TT Contact Person

Dr. Christian Schmees

+49 7121 51530 881

Download Flyer

Patient-Derived 3D Microtumour / T Cell Co-Cultures

Based on a panel of patient-derived micro-tumours (PDMs) and autologous PBMCs, we have established an advanced and versatile platform of CRO services for immuno-oncology (IO) research and drug development.

    We offer:
  • Cell-based service studies with dozens of patient-derived micro-tumour models (PDMs) and autologous immune cells (from whole blood-derived PBMCs and/or tumour-derived TILs), with full patient consent
  • Co-culture assays of micro-tumours with immune cells (e.g., PBMCs, antigen-specific T cells) and/or compounds
  • Performance of homogenous reader-based assays as well as high-content microscopy assays
  • Quantification of cytotoxicity induced by immune cells (e.g. antigen-specific T cells) alone and in combination with investigational compounds and/or combination therapies
  • Live-cell confocal 3D analysis of PDM infiltration by T lymphocytes
  • CRISPR-based genome editing of primary T cells


Linked in profile

NMI TT is a subsidiary of NMI